Researchers at the University of Tübingen and Novartis have demonstrated that changes in amyloid-β and tau protein levels in the cerebrospinal fluid of two mouse models of Alzheimer's disease track with observed changes in Aβ and tau levels in the CSF of human Alzheimer's patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.